{"id":"https://openalex.org/W70440412","doi":null,"title":"Receptor pharmacology of neuroleptics: relation to clinical effects.","display_name":"Receptor pharmacology of neuroleptics: relation to clinical effects.","publication_year":1999,"publication_date":"1999-01-01","ids":{"openalex":"https://openalex.org/W70440412","mag":"70440412","pmid":"https://pubmed.ncbi.nlm.nih.gov/10340682"},"language":"en","primary_location":{"id":"pmid:10340682","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10340682","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012485525","display_name":"Elliott Richelson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"E Richelson","raw_affiliation_strings":["Department of Psychiatry, Mayo Clinic and Foundation, Jacksonville, Fla 32224, USA. richel@mayo.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Mayo Clinic and Foundation, Jacksonville, Fla 32224, USA. richel@mayo.edu","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5012485525"],"corresponding_institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"],"apc_list":null,"apc_paid":null,"fwci":16.7918,"has_fulltext":false,"cited_by_count":306,"citation_normalized_percentile":{"value":0.9966082,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"60 Suppl 10","issue":null,"first_page":"5","last_page":"14"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9297000169754028,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9297000169754028,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0568000003695488,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8849999904632568},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9150000214576721},{"id":"https://openalex.org/keywords/receptor-pharmacology","display_name":"receptor pharmacology","score":0.9390000104904175},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":0.8209999799728394},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/sertindole","display_name":"sertindole","score":0.9990000128746033},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":1.0},{"id":"https://openalex.org/keywords/ziprasidone","display_name":"ziprasidone","score":1.0},{"id":"https://openalex.org/keywords/receptor-binding","display_name":"receptor binding","score":0.734000027179718},{"id":"https://openalex.org/keywords/therapeutic-effects","display_name":"therapeutic effects","score":0.6990000009536743},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.6769999861717224}],"concepts":[{"id":"https://openalex.org/C2780777758","wikidata":"https://www.wikidata.org/wiki/Q418050","display_name":"Sertindole","level":4,"score":0.9683454036712646},{"id":"https://openalex.org/C2777270317","wikidata":"https://www.wikidata.org/wiki/Q205517","display_name":"Ziprasidone","level":4,"score":0.898950457572937},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.8386430740356445},{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.8148037195205688},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.6166594624519348},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5568298101425171},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.44858667254447937},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.44557642936706543},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.440233051776886},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.30522048473358154},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.29678481817245483}],"mesh":[{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011954","descriptor_name":"Receptors, Dopamine","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011976","descriptor_name":"Receptors, Muscarinic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011985","descriptor_name":"Receptors, Serotonin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017981","descriptor_name":"Receptors, Neurotransmitter","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:10340682","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10340682","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},{"id":"mag:70440412","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10340682","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7910638233","display_name":"PSYCHOTROPIC DRUGS AND RECEPTOR SENSITIVITY CHANGES","funder_award_id":"R01MH027692","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"}],"funders":[{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2243407269","https://openalex.org/W2464113880","https://openalex.org/W2808049124","https://openalex.org/W4210475317","https://openalex.org/W1630084095","https://openalex.org/W2464526232","https://openalex.org/W1979700184","https://openalex.org/W4230590272","https://openalex.org/W2041829756","https://openalex.org/W196249647"],"abstract_inverted_index":{"This":[0],"article":[1],"reviews":[2],"the":[3,46,55,68],"receptor":[4,58],"pharmacology":[5],"of":[6,73],"neuroleptics,":[7],"with":[8],"a":[9],"focus":[10],"on":[11],"newer":[12,28],"drugs":[13],"(e.g.,":[14],"risperidone,":[15],"olanzapine,":[16],"sertindole,":[17],"quetiapine,":[18],"and":[19,70],"ziprasidone)":[20],"in":[21,56],"contrast":[22],"to":[23,32,67],"older":[24],"compounds.":[25],"All":[26],"these":[27,63,74],"compounds":[29,64],"are":[30,41,52,65],"considered":[31],"be":[33],"atypical":[34],"neuroleptics":[35],"based":[36],"upon":[37],"certain":[38],"criteria,":[39],"which":[40],"reviewed.":[42],"Several":[43],"hypotheses":[44],"about":[45],"molecular":[47],"mechanisms":[48],"that":[49],"explain":[50],"atypicality":[51],"considered.":[53],"Finally,":[54],"vitro":[57],"binding":[59],"data":[60],"presented":[61],"for":[62],"related":[66],"therapeutic":[69],"adverse":[71],"effects":[72],"drugs.":[75]},"counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}